| Chemical Properties | Back Directory | [Boiling point ]
1072.4±65.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:25.0(Max Conc. mg/mL);27.32(Max Conc. mM)
DMSO:25.0(Max Conc. mg/mL);27.32(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.33(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);10.93(Max Conc. mM) | [form ]
A crystalline solid | [pka]
15.82±0.46(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Description]
LH1307 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1. | [Uses]
LH1307 is a C2-symmetric inhibitor of PD-1/PD-L1 protein-protein interactions with a IC50 value of 3.0 μM and can be used in cancer studies[1]. | [in vitro]
C2-symmetric inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, respectively, in the HTRF assay. In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, respectively._x000D_
_x000D_
Reference: J Med Chem. 2019 Aug 8;62(15):7250-7263. https://pubmed.ncbi.nlm.nih.gov/31298541/ | [target]
LH1307 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1. | [storage]
Store at -20°C | [References]
[1] Basu S, et al. Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. J Med Chem. 2019 Aug 8;62(15):7250-7263. DOI:10.1021/acs.jmedchem.9b00795 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|